Cumberland Pharmaceuticals Outlines Five-Year Funding Plan Ahead of Ifetroban NDA Submission
Cumberland Pharmaceuticals (CPIX) has announced a strategic financial roadmap intended to fund its operations for more than five years. This capital positioning follows the company's first period of operation since completing a recent strategic transaction, marking a transition into a new phase of corporate development. The primary driver for this long-term funding strategy is the upcoming rolling New Drug Application (NDA) submission for ifetroban, which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company's management aims to provide stability as it moves toward regulatory milestones.
Tickers: $CPIX
Topics: earnings quarterly results strategic transaction
Read the full article at Seeking Alpha
Part of the story Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMD (2 articles)